Ozgun Alpaslan, Karagoz Bulent, Tuncel Tolga, Emirzeoglu Levent, Celik Serkan, Bilgi Oguz
Department of Medical Oncology, Gulhane Military Medical Academy, Haydarpasa Training Hospital, Istanbul, Turkey E-mail :
Asian Pac J Cancer Prev. 2013;14(11):6889-92. doi: 10.7314/apjcp.2013.14.11.6889.
Testicular germ cell tumors (TGCTs) are a relatively common malignancy in young men. The aim of this study was to investigate the clinicopathological features and survival of young Turkish patients with TGCT.
In this retrospective study, the clinical and pathological characteristics of young Turkish patients with TGCT who were monitored by the Department of Medical Oncology of a military hospital between 2008 and 2013 were investigated. Overall survival data were analyzed.
Ninety-six patients were included in the study. The mean age was 26.4 years. Among the patients, 17.7% had seminoma and 43.8% had mixed non-seminomatous germ cell tumors. Some 46.9% were Stage I, 30.2% were Stage II, and 22.9 were Stage III. Of the patients, 83.3% received chemotherapy, 25% underwent retroperitoneal lymph node dissection (RPLND), 3.1% received radiotherapy, and 12.5% were followed-up without treatment. In addition, 18.8% of the patients were administered salvage chemotherapy due to relapse or progression. The 5-year overall survival rate was 90.2% for all patients. The 2-year overall survival rate was 100% for Stage I patients, 94% for Stage II patients, and 70.2% for Stage III patients. The difference between the survival curves of stages was statistically significant (p=0.029).
In young Turkish patients with TGCT, good results were obtained with appropriate treatment, most receiving chemotherapy. The prognosis of the disease was good even in the advanced stage.
睾丸生殖细胞肿瘤(TGCTs)是年轻男性中相对常见的恶性肿瘤。本研究的目的是调查年轻土耳其TGCT患者的临床病理特征和生存率。
在这项回顾性研究中,调查了2008年至2013年期间在一家军队医院肿瘤内科接受监测的年轻土耳其TGCT患者的临床和病理特征。分析了总生存数据。
96例患者纳入研究。平均年龄为26.4岁。患者中,17.7%患有精原细胞瘤,43.8%患有混合性非精原生殖细胞肿瘤。约46.9%为I期,30.2%为II期,22.9%为III期。患者中,83%接受了化疗,25%接受了腹膜后淋巴结清扫术(RPLND),3.1%接受了放疗,12.5%未接受治疗仅进行随访。此外,18.8%的患者因复发或进展接受了挽救性化疗。所有患者的5年总生存率为90.2%。I期患者的2年总生存率为100%,II期患者为94%,III期患者为70.2%。各期生存曲线之间的差异具有统计学意义(p = 0.029)。
在年轻的土耳其TGCT患者中,通过适当的治疗取得了良好的效果,大多数患者接受了化疗。即使在晚期,该疾病的预后也较好。